Herein, we developed a versatile strategy for the synchronous screening of biomarkers of Alzheimer's disease (AD) by incorporating the high-resolution discrimination of an aerolysin nanopore to length-encoded oligonucleotides and the signal transduction of a triple-helix molecular switch (TMS). This assay is adapted to quantitatively compare multiplexed targets of very different native contents without tedious chemical labelling.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: